Rosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound

Bibliography

• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):S1-201
   Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care 2009;32(Suppl 1):S13-61
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy (A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:1-11
   Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Aldhahi W, Hamdy O. Adipokines, inflammation and the endothelium in diabetes. Curr Diab Rep 2003;3:293-8
   PubMedGoogle Scholar
• Lister CA, Moore GBT, Piercy V, et al. Rosiglitazone, but not metformin or glibenclamide, improves glycaemic control and increases islet insulin content [abstract]. Diabetologia 1999;42(Suppl 1):A150
   Google Scholar
• Finegood DT, McArthur MD, Kojwang D, et al. B-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 2001;50:1021-9
   PubMed Web of Science ®Google Scholar
• Bell DSH. Beta-cell rejuvenation with thiazolidinediones. Am J Med 2003;115:20S-23S
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43
   PubMed Web of Science ®Google Scholar
• Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-acitvated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
   PubMed Web of Science ®Google Scholar
• Holmes BF, Kurth-Kraczek EJ, Winder WW. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol 1999;87:1990-5
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline, Inc. Product monograph: Avandamet ®. March 2009
   Google Scholar
• Gerstein HC, Yusuf S, Bosch J, et al. for the DREAM (Diabetes Reduction Assessment with ramipirl and rosiglitazone medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006;368:1096-105
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
   PubMed Web of Science ®Google Scholar
• Fonseca V, Patwardhan R, Rosenstock A, et al. Effect of merformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 2000;283:1695-702
   PubMed Web of Science ®Google Scholar
• Jones TA, Sautter M, Van Gaal F, Jones NP. Addition of rosiglitazone to metformin is effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003;5:163-70
   PubMed Web of Science ®Google Scholar
• Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of Avandia added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the Empire Study. Curr Med Res Opin 2005;21(12):2029-35
   PubMed Web of Science ®Google Scholar
• Leiter LA, Harris SB, Chiasson JL, et al. Efficacy and safety of rosiglitazone as monotherapy or in combination with metformin in primary care settings. Can J Diab 2005;29(4):384-92
   Google Scholar
• Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2005;27(10):1548-61
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Rood J, Cobita A, et al. Improvement in glycemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycemic control. Diabetes Obes Metab 2006;8:643-9
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Rood J, Cobitz A, et al. Initial treatment with rosiglitazone/MET fixed –dose combination therapy compared with monotherapy with either rosiglitazone or MET in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006;8:650-60
   PubMed Web of Science ®Google Scholar
• Hamann A, Garcia-Puig J, Paul G, et al. Comparison of fixed-dose rosigliazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes 2008;116:6-13
   PubMed Web of Science ®Google Scholar
• Kelly IE, Hans TS, Walsh K, Lean ME. Effects of a thiazolidinediones compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22:288-93
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-8
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROACTIVE Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180(1).DOI:10.1503/cmaj.080-486
   PubMedGoogle Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298(10):1189-95
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Di Bari M, et al. Cardiac safety profile of rosigliatzone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2009, doi;10.1016/j.ijcard.2009.01.064
   PubMedGoogle Scholar
• Gerstein HC, Yusuf S, Bosch J, et al. DREAM (Diabetes Reduction Assessment with ramilpril and rosiglitazone). Effect of rosiglitazone on the frequency of diabetes in epatients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006;368:1096-105
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes–an interim analysis. N Engl J Med 2007;357(1):28-38
   PubMed Web of Science ®Google Scholar
• Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in perfused rat intestine. Biochem Pharmacol 2000;59:887-90
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic mellitus. N Engl J Med 1995;333:550-4
   PubMed Web of Science ®Google Scholar
• Lucis OJ. The status of metformin in Canada. CMAJ 1983;128:24-6
   PubMed Web of Science ®Google Scholar
• Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2003;2:CD002967
   PubMedGoogle Scholar
• Stades AM, Heikens JT, Erkelens DW, et al. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004;255:179-87
   PubMed Web of Science ®Google Scholar
• Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58(4):773-95
   PubMed Web of Science ®Google Scholar